OmniComm Systems, Inc.'s TrialMaster Phase 1 Version Chosen For 7 Studies By Catalyst Pharmaceutical Research
OmniComm Systems, Inc. (OTC BB: OMCM), one of the fastest growing companies in the EDC marketplace, announced today that the company's TrialMaster Ph. 1 EDC product has been selected by Catalyst Pharmaceutical Research for 7 phase 1 studies conducted on behalf of 5 different sponsor companies in just the first quarter of 2006.